RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Kiniksa Pharmaceuticals Stock

Kiniksa Pharmaceuticals Net Income 2024

Kiniksa Pharmaceuticals Net Income

-4.49 M USD

Ticker

KNSA

ISIN

BMG5269C1010

WKN

A2JMVJ

In 2024, Kiniksa Pharmaceuticals's profit amounted to -4.49 M USD, a -131.85% increase from the 14.08 M USD profit recorded in the previous year.

The Kiniksa Pharmaceuticals Net Income history

YEARNET INCOME (undefined USD)
2029e73.08
2028e62.95
2027e98.77
2026e55.48
2025e49.78
2024e-4.49
202314.08
2022183.4
2021-157.9
2020-161.4
2019-161.9
2018-103.2
2017-64.9
2016-24

Kiniksa Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Kiniksa Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Kiniksa Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Kiniksa Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Kiniksa Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Kiniksa Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Kiniksa Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Kiniksa Pharmaceuticals’s growth potential.

Kiniksa Pharmaceuticals Revenue, EBIT and net profit per share

DateKiniksa Pharmaceuticals RevenueKiniksa Pharmaceuticals EBITKiniksa Pharmaceuticals Net Income
2029e965.94 M undefined0 undefined73.08 M undefined
2028e750.8 M undefined84.66 M undefined62.95 M undefined
2027e795.02 M undefined81.63 M undefined98.77 M undefined
2026e705.77 M undefined94.29 M undefined55.48 M undefined
2025e566.99 M undefined22.14 M undefined49.78 M undefined
2024e420.08 M undefined-25.8 M undefined-4.49 M undefined
2023270.26 M undefined-25.2 M undefined14.08 M undefined
2022220.2 M undefined9.8 M undefined183.4 M undefined
202138.5 M undefined-156.6 M undefined-157.9 M undefined
20200 undefined-157.4 M undefined-161.4 M undefined
20190 undefined-170 M undefined-161.9 M undefined
20180 undefined-108.2 M undefined-103.2 M undefined
20170 undefined-65.4 M undefined-64.9 M undefined
20160 undefined-24 M undefined-24 M undefined

Kiniksa Pharmaceuticals stock margins

The Kiniksa Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Kiniksa Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Kiniksa Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Kiniksa Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Kiniksa Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Kiniksa Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Kiniksa Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Kiniksa Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Kiniksa Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Kiniksa Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Kiniksa Pharmaceuticals Margin History

Kiniksa Pharmaceuticals Gross marginKiniksa Pharmaceuticals Profit marginKiniksa Pharmaceuticals EBIT marginKiniksa Pharmaceuticals Profit margin
2029e87.64 %0 %7.57 %
2028e87.64 %11.28 %8.38 %
2027e87.64 %10.27 %12.42 %
2026e87.64 %13.36 %7.86 %
2025e87.64 %3.91 %8.78 %
2024e87.64 %-6.14 %-1.07 %
202387.64 %-9.32 %5.21 %
202289.6 %4.45 %83.29 %
202176.36 %-406.75 %-410.13 %
202087.64 %0 %0 %
201987.64 %0 %0 %
201887.64 %0 %0 %
201787.64 %0 %0 %
201687.64 %0 %0 %

Kiniksa Pharmaceuticals Aktienanalyse

What does Kiniksa Pharmaceuticals do?

Kiniksa Pharmaceuticals Ltd is a US biotech company founded in 2015 and headquartered in Lexington, Massachusetts. The company specializes in the development and commercialization of therapies for rare and chronic inflammatory diseases. Kiniksa Pharmaceuticals' business model is based on collaboration with leading scientists and clinicians to develop innovative solutions for patients with complex clinical needs. The company's products focus on various inflammatory diseases and have multiple candidates in the pipeline for different indications in clinical development. Kiniksa Pharmaceuticals has also focused on developing therapies for rare diseases. A key feature of the company is its high-throughput platform, which allows for the identification and validation of potential therapeutics in a short amount of time. Kiniksa Pharmaceuticals was founded in 2015 by former executives from Biogen and Vertex Pharmaceuticals who had extensive experience in the discovery and development of drugs for chronic inflammatory diseases. The company quickly received an initial funding of $60 million and has since sought additional financing to expand its technology platform and scientific expertise. Kiniksa Pharmaceuticals consists of several divisions, including the development division, which is responsible for the clinical development of therapeutics for rare and chronic inflammatory diseases. Another important division is product development, which specializes in the identification and validation of candidates for potential therapeutics. This includes the identification of biomarkers that can serve as indicators of drug effectiveness. Kiniksa Pharmaceuticals also has a marketing division responsible for the commercialization of already approved products. The products of Kiniksa Pharmaceuticals focus on the treatment of inflammatory diseases. One of the key candidates currently in clinical development is KPL-716, a potential monoclonal antibody that can be used for multiple indications, including cutaneous T-cell lymphoma and chronic obstructive asthma. Another important potential is the candidate Mavrilimumab, a potential monoclonal antibody that can be used for the treatment of giant cell arteritis and polymyalgia rheumatica. Other key candidates include KPL-404, a potential monoclonal antibody that can be used for the treatment of ulcerative colitis. Overall, Kiniksa Pharmaceuticals has a promising future by focusing on innovative products for rare and chronic inflammatory diseases. Kiniksa Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Kiniksa Pharmaceuticals's Profit Margins

The profit margins of Kiniksa Pharmaceuticals represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Kiniksa Pharmaceuticals's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Kiniksa Pharmaceuticals's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Kiniksa Pharmaceuticals's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Kiniksa Pharmaceuticals’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Kiniksa Pharmaceuticals stock

How much profit has Kiniksa Pharmaceuticals made this year?

Kiniksa Pharmaceuticals has made -4.49 M USD this year.

How has the profit developed compared to last year?

The profit has increased by -131.85% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Kiniksa Pharmaceuticals publish its earnings?

Kiniksa Pharmaceuticals publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Kiniksa Pharmaceuticals?

The profits of Kiniksa Pharmaceuticals are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Kiniksa Pharmaceuticals?

You can learn more about the earnings of Kiniksa Pharmaceuticals by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Kiniksa Pharmaceuticals pay?

Over the past 12 months, Kiniksa Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Kiniksa Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Kiniksa Pharmaceuticals?

The current dividend yield of Kiniksa Pharmaceuticals is .

When does Kiniksa Pharmaceuticals pay dividends?

Kiniksa Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Kiniksa Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kiniksa Pharmaceuticals located?

Kiniksa Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kiniksa Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kiniksa Pharmaceuticals from 7/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/30/2024.

When did Kiniksa Pharmaceuticals pay the last dividend?

The last dividend was paid out on 7/30/2024.

What was the dividend of Kiniksa Pharmaceuticals in the year 2023?

In the year 2023, Kiniksa Pharmaceuticals distributed 0 USD as dividends.

In which currency does Kiniksa Pharmaceuticals pay out the dividend?

The dividends of Kiniksa Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Kiniksa Pharmaceuticals

Our stock analysis for Kiniksa Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kiniksa Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.